In the last six months, Pear Therapeutics has raised $100 million, inked a bevy of new deals, and launched a sweeping study of its app to treat substance use disorders.
It has also seen a high-profile study on its digital treatment for schizophrenia fail.
The frenetic pace of developments is a reflection of the ambitions at Pear, an eight-year-old health tech company which gained prominence by winning Food and Drug Administration clearance for prescription digital therapeutics. It’s now pushing forward with an aggressive strategy to convince doctors and insurers that software can be medicine for all sorts of diseases. The Boston- and San Francisco-based company already has three FDA-authorized treatments on the market, over a dozen products in the pipeline, and new technologies in the works. But Pear is also setting its sights outside of its own products, teasing the idea that it might one day provide the tech scaffolding on which a broad market of digital health tools could be built.
About the Author Reprints
